Pharmacotherapy of Dilated Cardiomyopathy

J 2015

Pharmacotherapy of Dilated Cardiomyopathy

ŠPINAROVÁ, Lenka a Jindřich ŠPINAR

Základní údaje

Originální název

Pharmacotherapy of Dilated Cardiomyopathy

Autoři

ŠPINAROVÁ, Lenka a Jindřich ŠPINAR

Vydání

Current Pharmaceutical Design, Sharjah, Bentham Science Publishers, 2015, 1381-6128

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené arabské emiráty

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.052

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00082269

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Dilated cardiomyopathy; pharmacological treatment; acute decompensation

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 7. 2015 10:33, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

The pharmacological treatment of dilated cardiomyopathy overlaps with the treatment of heart failure. The primary objective of this treatment is to slow the progression of disease and improve quality and length of life. All patients, including those with asymptomatic dysfunction of the left ventricle, ought to receive angiotensin converting enzyme inhibitors, (in the case of intolerance, angiotensin receptor blockers), and beta blockers. The results of studies involving aliskiren have been, so far, disappointing. In symptomatic heart failure NYHA II-IV diuretics and mineralcorticoid receptor antagonists should be added to treatment. Digoxin is recommended in the event of atrial fibrillation, and otherwise only in the event of NYHA III and IV. Ivabradine is recommended for patients with sinus rhythm and pulse rate of > 70/min. In decompensation of heart failure, dobutamine, phosphodiesterase inhibitors or levosimendan are administered over the short-term. Of the recent treatment options, the vasopressin blocker and adenosine A1 receptor antagonist (rolofylline) were disappointing. One treatment with potential for the future is omecamtiv mecarbil, a heart myosin activator.

Citovat

ŠPINAROVÁ, Lenka a Jindřich ŠPINAR. Pharmacotherapy of Dilated Cardiomyopathy. Current Pharmaceutical Design. Sharjah: Bentham Science Publishers, 2015, roč. 21, č. 4, s. 449-458. ISSN 1381-6128. Dostupné z: https://doi.org/10.2174/138161282104141204141851.

@article{1217420,
   author = {Špinarová, Lenka and Špinar, Jindřich},
   article_location = {Sharjah},
   article_number = {4},
   doi = {https://doi.org/10.2174/138161282104141204141851},
   keywords = {Dilated cardiomyopathy; pharmacological treatment; acute decompensation},
   language = {eng},
   issn = {1381-6128},
   journal = {Current Pharmaceutical Design},
   title = {Pharmacotherapy of Dilated Cardiomyopathy},
   volume = {21},
   year = {2015}
}

TY  - JOUR
ID  - 1217420
AU  - Špinarová, Lenka - Špinar, Jindřich
PY  - 2015
TI  - Pharmacotherapy of Dilated Cardiomyopathy
JF  - Current Pharmaceutical Design
VL  - 21
IS  - 4
SP  - 449-458
EP  - 449-458
PB  - Bentham Science Publishers
SN  - 13816128
KW  - Dilated cardiomyopathy
KW  - pharmacological treatment
KW  - acute decompensation
N2  - The pharmacological treatment of dilated cardiomyopathy overlaps with the treatment of heart failure. The primary objective of this treatment is to slow the progression of disease and improve quality and length of life. All patients, including those with asymptomatic dysfunction of the left ventricle, ought to receive angiotensin converting enzyme inhibitors, (in the case of intolerance, angiotensin receptor blockers), and beta blockers. The results of studies involving aliskiren have been, so far, disappointing. In symptomatic heart failure NYHA II-IV diuretics and mineralcorticoid receptor antagonists should be added to treatment. Digoxin is recommended in the event of atrial fibrillation, and otherwise only in the event of NYHA III and IV. Ivabradine is recommended for patients with sinus rhythm and pulse rate of > 70/min. In decompensation of heart failure, dobutamine, phosphodiesterase inhibitors or levosimendan are administered over the short-term. Of the recent treatment options, the vasopressin blocker and adenosine A1 receptor antagonist (rolofylline) were disappointing. One treatment with potential for the future is omecamtiv mecarbil, a heart myosin activator.
ER  -

ŠPINAROVÁ, Lenka a Jindřich ŠPINAR. Pharmacotherapy of Dilated Cardiomyopathy. \textit{Current Pharmaceutical Design}. Sharjah: Bentham Science Publishers, 2015, roč.~21, č.~4, s.~449-458. ISSN~1381-6128. Dostupné z: https://doi.org/10.2174/138161282104141204141851.

Přehled o publikaci